---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-22-063262"
form_type: "8-K"
ticker: "CBIO"
cik: "0001253689"
company_name: "CRESCENT BIOPHARMA, INC."
filed_at: "2022-05-20T23:59:59+00:00"
generated_at: "2026-06-25T08:36:33.679445+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# GlycoMimetics stockholders approve 2.6M share increase to equity incentive plan

## Summary
- Stockholders approved amendment to 2013 Equity Incentive Plan, increasing share reserve by 2,619,622 shares.
- All three director nominees (Scott Jackson, Scott Koenig, Harout Semerjian) were elected.
- Ratification of Ernst & Young as independent auditor passed with 38,971,830 votes for.
- Advisory vote on executive compensation approved with 27,132,991 votes for.
- Annual meeting had 75% of shares present or represented.

## SEC filing metadata
- accession: 0001104659-22-063262
- form_type: 8-K
- ticker: CBIO
- cik: 0001253689
- company_name: CRESCENT BIOPHARMA, INC.
- filed_at: 2022-05-20T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.02, 5.07, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1253689/000110465922063262/0001104659-22-063262-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1253689/000110465922063262/tm2216126d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-22-063262
- JSON: https://secwatch.observer/filing/0001104659-22-063262.json
- Plain text: https://secwatch.observer/filing/0001104659-22-063262.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.